AbbVie Presents Data on Eight-Week Treatment of VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA(R) (dasabuvir tablets) in Patients with Genotype 1b Chronic Hepatitis C

NORTH CHICAGO, Ill., Sept. 23, 2016 -- (Healthcare Sales & Marketing Network) -- AbbVie (ABBV), a global biopharmaceutical company, today announced new data showing high response rates with just eight weeks of VIEKIRAX® (ombitasvir/paritaprevir/ritona... Biopharmaceuticals AbbVie, hepatitis C, VIEKIRAX, EXVIERA
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news